Compare ONEW & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | KALA |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.6M | 172.0M |
| IPO Year | 2019 | 2017 |
| Metric | ONEW | KALA |
|---|---|---|
| Price | $10.79 | $2.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $16.50 | ★ $31.50 |
| AVG Volume (30 Days) | 122.7K | ★ 2.2M |
| Earning Date | 04-30-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $3.85 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $0.07 |
| 52 Week High | $17.92 | $20.58 |
| Indicator | ONEW | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 65.40 |
| Support Level | $10.23 | $0.32 |
| Resistance Level | $12.31 | $3.96 |
| Average True Range (ATR) | 0.62 | 0.30 |
| MACD | -0.08 | 0.07 |
| Stochastic Oscillator | 38.04 | 62.02 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.